Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Randi Isaacs"'
Autor:
Christopher J Nirschl, Kyriakos Economides, Kristin Morris, Andres Salmeron, Daniel J Hicklin, Cynthia Seidel-Dugan, Kulandayan K Subramanian, Randi Isaacs, Sameer Chopra, Celesztina Domonkos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/cf1f1cc9b0be40e987cd30bbaf33f839
Autor:
Brendan Curti, Igor Puzanov, Mateusz Opyrchal, Christopher J Nirschl, Mehmet A Bilen, Kristin Morris, Justin C Moser, Ildefonso Rodriguez Rivera, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2c535f528fe849388924b327f27fc65e
Autor:
Ildefonso Ismael Rodriguez-Rivera, Justin C. Moser, Mateusz Opyrchal, Aparna R. Parikh, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K. Subramanian, Sameer S. Chopra, Randi Isaacs
Publikováno v:
Cancer Research. 83:CT254-CT254
Background: Interleukin-12 (IL-12) is a potent proinflammatory cytokine with activating effects on both innate and adaptive immune cells. Though recombinant IL-12 (rIL-12) causes tumor regression with antitumor immune memory formation in a range of i
Publikováno v:
Anticancer Research. 40:5229-5235
Background/aim The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclini
Autor:
Roberto Buzzoni, W.P. Yong, S. Reingold, Joseph McKendrick, G.J.M. Creemers, Fernando Rivera, Dewi Vernerey, David Cunningham, G. Ravit, E. Van Cutsem, Jin-Tung Liang, A. de Gramont, Pia Österlund, G. Bodoky, Thierry André, J. Tabernero, W. Scheithauer, Randi Isaacs, Manel Rakez, S-A. Im, G. Fountzilas
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Background The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here
Autor:
Georgios Z. Papadakis, Randi Isaacs, Jason A Berglund, Jaydira Del Rivero, Kelly L Roszko, Jing Tassone, Rachel I Gafni, Michael T. Collins, Pablo Florenzano, Clemens Bergwitz, Jenny E Blau, Carole B. Miller, Susan Moran, Iris R Hartley
Publikováno v:
N Engl J Med
Targeted FGFR Blockade for Tumor-Induced Osteomalacia This letter describes the treatment of a patient with tumor-induced osteomalacia due to a phosphaturic mesenchymal tumor. The discovery of FN1–...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8598b3d9628d29d96497f68186480b3e
https://europepmc.org/articles/PMC7561341/
https://europepmc.org/articles/PMC7561341/
Autor:
Dale Porter, Sunil Sharma, Juergen Wolf, Jae-Lyun Lee, Kun Yu, Matthew D. Galsky, Jan H.M. Schellens, Daniel P. Petrylak, Ugo De Giorgi, Jean H. Hoffman-Censits, Jean Pierre Delord, Jonathan E. Rosenberg, Raanan Berger, Amir Mortazavi, Chaiyut Charoentum, Christian Dittrich, Ulka N. Vaishampayan, Randi Isaacs, Dean F. Bajorin, Katie Parker, Gwenaelle Gravis, Diana Graus Porta, Xueying Chen, Howard A. Burris, Jens Voortman, Eliahu Gez, David I. Quinn, Pablo Maroto, Bhumsuk Keam, David J. Vaughn, Viktor Grünwald, Sumanta K. Pal, Sumati Gupta, Virote Sriuranpong, J. Medioni
Publikováno v:
Cancer Discovery
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cancer discovery, 8(7), 812-821. American Association for Cancer Research Inc.
Pal, S K, Rosenberg, J E, Hoffman-Censits, J H, Berger, R, Quinn, D I, Galsky, M D, Wolf, J, Dittrich, C, Keam, B, Delord, J-P, Schellens, J H M, Gravis, G, Medioni, J, Maroto, P, Sriuranpong, V, Charoentum, C, Burris, H A, Grünwald, V, Petrylak, D, Vaishampayan, U, Gez, E, de Giorgi, U, Lee, J-L, Voortman, J, Gupta, S, Sharma, S, Mortazavi, A, Vaughn, D J, Isaacs, R, Parker, K, Chen, X, Yu, K, Porter, D, Porta, D G & Bajorin, D F 2018, ' Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations ', Cancer discovery, vol. 8, no. 7, pp. 812-821 . https://doi.org/10.1158/2159-8290.CD-18-0229
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Cancer discovery, 8(7), 812-821. American Association for Cancer Research Inc.
Pal, S K, Rosenberg, J E, Hoffman-Censits, J H, Berger, R, Quinn, D I, Galsky, M D, Wolf, J, Dittrich, C, Keam, B, Delord, J-P, Schellens, J H M, Gravis, G, Medioni, J, Maroto, P, Sriuranpong, V, Charoentum, C, Burris, H A, Grünwald, V, Petrylak, D, Vaishampayan, U, Gez, E, de Giorgi, U, Lee, J-L, Voortman, J, Gupta, S, Sharma, S, Mortazavi, A, Vaughn, D J, Isaacs, R, Parker, K, Chen, X, Yu, K, Porter, D, Porta, D G & Bajorin, D F 2018, ' Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations ', Cancer discovery, vol. 8, no. 7, pp. 812-821 . https://doi.org/10.1158/2159-8290.CD-18-0229
BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enr
Autor:
Daniel J. Hicklin, Jenna Sullivan, Andres Salmeron, Ethika Tyagi, Philipp Steiner, Kristin Morris, Heather Brodkin, Christopher J. Nirschl, Zoe Steuert, William Winston, Josue Canales, Cindy Seidel-Dugan, Nesreen Ismail, Randi Isaacs
Publikováno v:
Blood. 138:2258-2258
Systemic therapy with proinflammatory immune modulators to activate anti-tumor immunity is a promising approach to treat cancer. However, poor pharmacokinetic properties and dose-limiting toxicities such as inflammation, cytokine release syndrome, an
Autor:
Simon F. Lacey, Eric Lancaster, Fang Chen, Edward A. Stadtmauer, Don L. Siegel, J. Joseph Melenhorst, Iulian Pruteanu-Malinici, Regina M. Young, Dan T. Vogl, Karen Dengel, Annemarie Nelson, Wei-Ting Hwang, Brendan M. Weiss, Adam D. Cohen, Bruce L. Levine, Alfred L. Garfall, Michael C. Milone, Carl H. June, Megan M. Davis, Jennifer Brogdon, Randi Isaacs, Gabriela Plesa
Publikováno v:
J Clin Invest
BACKGROUND. CAR T cells are a promising therapy for hematologic malignancies. B cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM). METHODS. We conducted a phase I study of autologous T cells lentivirally transduced with a f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5624fbd7933095116425e48e29e0cca6
https://europepmc.org/articles/PMC6546468/
https://europepmc.org/articles/PMC6546468/
Autor:
Andrea L. Brennan, Lifeng Tian, Jamie Guilliams, Andrew D. Fesnak, Eric Lancaster, Randi Isaacs, Simon F. Lacey, Alfred L. Garfall, Regina M. Young, Michael C. Milone, Jennifer Brogdon, Adam Waxman, Bruce L. Levine, Edward A. Stadtmauer, Regina Ferthio, Adam D. Cohen, Wei-Ting Hwang, Dan T. Vogl, Anne Lamontagne, Whitney L. Gladney, Carl H. June, Don L. Siegel, Anne Marie Nelson, J. Joseph Melenhorst
Publikováno v:
Blood. 134:1863-1863
BACKGROUND: Anti-BCMA CAR T cells are effective in relapsed/refractory multiple myeloma (RRMM), but most patients eventually progress. Extensive prior therapy and high disease burden in RRMM pts may compromise CAR T cell safety, feasibility, and effi